p.Arg72Pro polymorphism of P53 and breast cancer risk: a meta-analysis of case-control studies.
Breast cancer
Meta-analysis
P53 gene
p.Arg/pro polymorphism
Journal
BMC medical genetics
ISSN: 1471-2350
Titre abrégé: BMC Med Genet
Pays: England
ID NLM: 100968552
Informations de publication
Date de publication:
19 10 2020
19 10 2020
Historique:
received:
22
11
2019
accepted:
24
09
2020
entrez:
20
10
2020
pubmed:
21
10
2020
medline:
3
11
2020
Statut:
epublish
Résumé
The effect of the p.Arg72Pro variant of the P53 gene on the risk of development ofbreast cancer remains variable in populations. However, the use ofstrategies such aspoolingage-matched controls with disease may provide a consistent meta-analysis. Our goal was to perform a meta-analysis in order to assess the association of p.Arg72Pro variant of P53 gene with the risk of breast cancer. Databases such as PubMed, Genetics Medical Literature, Harvard University Library, Web of Science and Genesis Library were used to search articles. Case-control studies with age-matched on breast cancer havingevaluated the genotype frequencies of the TP53 p.Arg72Pro polymorphism were selected. The fixed and random effects (Mantel-Haenszel) were calculated using pooled odds ratio of 95% CI to determine the risk of disease. Inconsistency was calculated to determine heterogeneity among the studies. The publication bias was estimated using the funnel plot. Twenty-one publications with 7841 cases and 8876 controls were evaluated in this meta-analysis. Overall, our results suggested that TP53 p.Arg72Pro was associated with the risk of breast cancer for the dominant model (OR = 1.09, 95% CI = 1.02-1.16, P = 0.01) and the additive model (OR = 1.09, 95% CI = 1.01-1.17, P = 0.03), but not for the recessive model (OR = 1.07, 95% CI = 0.97-1.18, P = 0.19). According to the ethnic group analysis, Pro allele was associated with the risk of breast cancer in Caucasians for the dominant model and additive model (P = 0.02), and Africans for the recessive model and additive model (P = 0.03). This meta-analysis found a significant association between TP53 p.Arg72Pro polymorphism and the risk of breast cancer. Individuals carrying at least one Pro allele were more likely to have breast cancer than individuals harboring the Arg allele.
Sections du résumé
BACKGROUND
The effect of the p.Arg72Pro variant of the P53 gene on the risk of development ofbreast cancer remains variable in populations. However, the use ofstrategies such aspoolingage-matched controls with disease may provide a consistent meta-analysis. Our goal was to perform a meta-analysis in order to assess the association of p.Arg72Pro variant of P53 gene with the risk of breast cancer.
METHODS
Databases such as PubMed, Genetics Medical Literature, Harvard University Library, Web of Science and Genesis Library were used to search articles. Case-control studies with age-matched on breast cancer havingevaluated the genotype frequencies of the TP53 p.Arg72Pro polymorphism were selected. The fixed and random effects (Mantel-Haenszel) were calculated using pooled odds ratio of 95% CI to determine the risk of disease. Inconsistency was calculated to determine heterogeneity among the studies. The publication bias was estimated using the funnel plot.
RESULTS
Twenty-one publications with 7841 cases and 8876 controls were evaluated in this meta-analysis. Overall, our results suggested that TP53 p.Arg72Pro was associated with the risk of breast cancer for the dominant model (OR = 1.09, 95% CI = 1.02-1.16, P = 0.01) and the additive model (OR = 1.09, 95% CI = 1.01-1.17, P = 0.03), but not for the recessive model (OR = 1.07, 95% CI = 0.97-1.18, P = 0.19). According to the ethnic group analysis, Pro allele was associated with the risk of breast cancer in Caucasians for the dominant model and additive model (P = 0.02), and Africans for the recessive model and additive model (P = 0.03).
CONCLUSIONS
This meta-analysis found a significant association between TP53 p.Arg72Pro polymorphism and the risk of breast cancer. Individuals carrying at least one Pro allele were more likely to have breast cancer than individuals harboring the Arg allele.
Identifiants
pubmed: 33076844
doi: 10.1186/s12881-020-01133-8
pii: 10.1186/s12881-020-01133-8
pmc: PMC7574232
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Meta-Analysis
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
206Subventions
Organisme : FIC NIH HHS
ID : D43 TW010543
Pays : United States
Organisme : FIC NIH HHS
ID : U2R TW010673
Pays : United States
Références
Nat Rev Genet. 2010 May;11(5):356-66
pubmed: 20395969
BMC Cancer. 2008 Jan 29;8:32
pubmed: 18230179
Int J Cancer. 2011 Aug 15;129(4):920-30
pubmed: 20886596
Mol Cell Biol Res Commun. 2000 Jun;3(6):389-92
pubmed: 11032762
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
NPJ Breast Cancer. 2017 Feb 27;3:5
pubmed: 28649645
Curr Genomics. 2018 Aug;19(5):395-410
pubmed: 30065615
Control Clin Trials. 1986 Sep;7(3):177-88
pubmed: 3802833
BMC Cancer. 2017 Nov 13;17(1):758
pubmed: 29132330
Int J Cancer. 2007 Oct 1;121(7):1481-6
pubmed: 17546594
Nat Genet. 2003 Mar;33(3):357-65
pubmed: 12567188
Mol Cell Biochem. 2003 Oct;252(1-2):117-24
pubmed: 14577584
Cell Death Dis. 2013 Feb 14;4:e492
pubmed: 23412385
BMC Cancer. 2019 Feb 1;19(1):118
pubmed: 30709381
Breast Cancer Res Treat. 2011 Jan;125(1):201-5
pubmed: 20496166
Cancer Lett. 2004 Jul 16;210(2):197-203
pubmed: 15183535
Oncol Rep. 2003 May-Jun;10(3):711-4
pubmed: 12684648
Springerplus. 2014 Dec 17;3:749
pubmed: 26034701
Cell Rep. 2016 Mar 15;14(10):2413-25
pubmed: 26947067
Cell. 2005 Jul 15;122(1):21-32
pubmed: 16009130
J Exp Clin Cancer Res. 2009 Aug 14;28:115
pubmed: 19682377
Ann Epidemiol. 2008 Jan;18(1):48-57
pubmed: 17719241
Cancer Detect Prev. 2006;30(6):523-9
pubmed: 17113725
Curr Pharm Des. 2018;24(30):3566-3575
pubmed: 30255744
Med Oncol. 2011 Sep;28(3):709-15
pubmed: 20443084
Pathol Oncol Res. 2009 Sep;15(3):359-68
pubmed: 19048399
Int J Cancer. 2008 Aug 1;123(3):577-85
pubmed: 18498133
Carcinogenesis. 2006 Apr;27(4):766-71
pubmed: 16314399
Nat Cell Biol. 2008 Sep;10(9):1098-105
pubmed: 19160491
Pathobiology. 2018;85(4):247-253
pubmed: 29949804
Genes Dev. 2018 Feb 1;32(3-4):230-243
pubmed: 29463573
Int J Cancer. 2010 Dec 15;127(12):2893-917
pubmed: 21351269
Breast Cancer Res Treat. 2008 Nov;112(1):81-7
pubmed: 18058229
Cold Spring Harb Perspect Med. 2016 May 02;6(5):
pubmed: 27141080
Pathobiology. 2018;85(3):186-191
pubmed: 29131100
Cancer Genet Cytogenet. 2009 Jul 15;192(2):93-5
pubmed: 19596263
Oncol Rep. 2009 Nov;22(5):1205-11
pubmed: 19787241
Fam Cancer. 2014 Jun;13(2):173-80
pubmed: 24114315
BMJ. 1997 Sep 13;315(7109):629-34
pubmed: 9310563
Clin Transl Oncol. 2016 Jul;18(7):728-34
pubmed: 26553387
Tumour Biol. 2014 Sep;35(9):9219-27
pubmed: 24929325
Nat Rev Genet. 2010 Apr;11(4):259-72
pubmed: 20212493
Am J Epidemiol. 2013 Jun 15;177(12):1317-25
pubmed: 23729685
Hum Mol Genet. 2011 Oct 15;20(20):4082-92
pubmed: 21798870
Exp Ther Med. 2013 May;5(5):1397-1402
pubmed: 23737888
Cancer. 2002 Dec 15;95(12):2571-6
pubmed: 12467072
Saudi Med J. 2004 Nov;25(11):1568-73
pubmed: 15573180
Eur J Gynaecol Oncol. 2010;31(5):539-44
pubmed: 21061796
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2007 Nov;36(6):561-6
pubmed: 18067229
BMC Med Genet. 2020 Jul 3;21(1):142
pubmed: 32620097
Clin Cancer Res. 2009 Oct 1;15(19):6292-300
pubmed: 19789321
Br J Cancer. 2005 Mar 28;92(6):1144-8
pubmed: 15756275
Tumour Biol. 2016 Jun;37(6):7229-37
pubmed: 26666818
Int J Gynecol Pathol. 2002 Oct;21(4):401-6
pubmed: 12352189
Br J Cancer. 2004 May 17;90(10):1989-94
pubmed: 15138483
Asian Pac J Cancer Prev. 2020 Jun 01;21(6):1511-1519
pubmed: 32592343
N Engl J Med. 2006 Jan 19;354(3):270-82
pubmed: 16421368
J Cancer Res Clin Oncol. 2010 Sep;136(9):1369-75
pubmed: 20127253
Fundam Clin Pharmacol. 2012 Jun;26(3):438-43
pubmed: 21477265
Oncol Res. 2009;18(1):25-30
pubmed: 19911701
Carcinogenesis. 2007 Aug;28(8):1680-6
pubmed: 17449902
Nat Rev Cancer. 2016 Apr;16(4):251-65
pubmed: 27009395
Anticancer Res. 2015 Mar;35(3):1763-9
pubmed: 25750340
Genet Res (Camb). 2015 Apr 17;97:e7
pubmed: 25882871
Lancet. 2005 May 14-20;365(9472):1727-41
pubmed: 15894099
Int J Mol Med. 2009 Mar;23(3):429-35
pubmed: 19212663
Oncol Rep. 2009 Dec;22(6):1425-33
pubmed: 19885596
Asian Pac J Cancer Prev. 2014;15(16):6871-9
pubmed: 25169539
Pharmacogenetics. 2002 Apr;12(3):269-72
pubmed: 11927843
DNA Cell Biol. 2012 Mar;31(3):306-16
pubmed: 21838531
Cancer Causes Control. 2007 Aug;18(6):621-5
pubmed: 17387621
Breast Cancer. 2017 Jul;24(4):571-578
pubmed: 27837441